Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
17.97
-0.11 (-0.58%)
May 4, 2026, 2:55 PM EDT - Market open
Crescent Biopharma Revenue
Crescent Biopharma had revenue of $1.04M in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $11.88M. In the year 2025, Crescent Biopharma had annual revenue of $10.84M.
Revenue (ttm)
$11.88M
Revenue Growth
n/a
P/S Ratio
51.20
Revenue / Employee
$270,068
Employees
44
Market Cap
596.96M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.84M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 10.00K | -65.00K | -86.67% |
| Dec 31, 2022 | 75.00K | -1.08M | -93.53% |
| Dec 31, 2021 | 1.16M | -9.00M | -88.59% |
| Dec 31, 2020 | 10.16M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | 18.50M | -1.57M | -7.83% |
| Dec 31, 2015 | 20.07M | 5.04M | 33.56% |
| Dec 31, 2014 | 15.03M | 11.03M | 276.37% |
| Dec 31, 2013 | 3.99M | -11.26M | -73.83% |
| Dec 31, 2012 | 15.26M | 11.44M | 300.05% |
| Dec 31, 2011 | 3.81M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 389.42M |
| CorMedix | 311.71M |
| Ginkgo Bioworks Holdings | 170.16M |
| Zevra Therapeutics | 106.47M |
| Sutro Biopharma | 102.48M |
| Prothena Corporation | 9.68M |
| Aclaris Therapeutics | 7.83M |
| Adlai Nortye | 5.00M |
CBIO News
- 4 days ago - Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 9 days ago - Crescent Biopharma Announces Grants of Inducement Awards - GlobeNewsWire
- 7 weeks ago - Crescent Biopharma Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Crescent Biopharma Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - Crescent Biopharma to Present at March Investor Conferences - GlobeNewsWire
- 2 months ago - Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors - GlobeNewsWire
- 2 months ago - Crescent Biopharma Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - Transcripts